EU/3/07/439

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal poducts in December 2010 on request of the sponsor.

On 20 March 2007, orphan designation EU/3/07/439 was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class for the treatment of cryopirin-associated periodic syndromes (familial cold urticaria syndrome (FCUS), Muckle-Wells syndrome (MWS), and neonatal onset multisystem inflammatory disease (NOMID), also known as chronic infantile neurological cutaneous articular syndrome (CINCA).

Recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class has been authorised in the EU as Ilaris since 23 October 2009.

Key facts

Active substance
Recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class
Medicine name
Ilaris
Disease / condition
Treatment of cryopirin-associated periodic syndromes (FCUS, MWS, and NOMID)
Date of first decision
20/03/2007
Outcome
Withdrawn
EU designation number
EU/3/07/439

Review of designation

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in December 2010 on request of the sponsor, after the granting of a marketing authorisation.

Sponsor's contact details

Novartis Europharm Limited
Frimley Business Park
Camberley GU16 7SR
United Kingdom
Tel. +41 61 324 11 11 (Switzerland)
E-mail: orphan.enquiries@novartis.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating